Phase I Clinical and Pharmacokinetic Study of Kahalalide F Administered Weekly as a 1-Hour Infusion to Patients with Advanced Solid Tumors .

Resultados de Fase I en Tumores Solidos y Dosis Recomendada para la Fase II .